Ovid Therapeutics Profit Margin

The latest profit margin for OVID is -339.31% as of March 2026. That compares with -4557.12% in the prior-year period — up 92.6% year over year. That is below the Healthcare sector average of 14.34%. Investors often review this figure alongside Ovid Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, OVID's profit margin moved from -4557.12% to -339.31% — a 92.6% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Ovid Therapeutics's valuation or profitability profile.

Against Healthcare companies, OVID currently prints -339.31% for profit margin, while the sector average sits near 14.34%. That is roughly 2465.4% below the sector mean. Large gaps often invite a closer look at Ovid Therapeutics's growth, margins, and balance sheet.

Profit Margin shows how effectively Ovid Therapeutics converts resources into returns. At -339.31%, OVID may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -4557.12% in the prior-year period — up 92.6% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting OVID's profit margin (-339.31%), review year-over-year change from -4557.12%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.